Regeneron inks $1B+ deal for global rights to Sanofi-partnered PD-1 Libtayo

Nicole DeFeudis

Editor

Sanofi CEO Paul Hudson made clear earlier this year that his mission to reshape the company would involve some pipeline pruning. For the right price …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regeneron inks $1B+ deal for global rights to Sanofi-partnered PD-1 Libtayo

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Alcon tried to sink Aurion's IPO in 'Valentine's Day massacre,' new lawsuits say

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

How AI can address ongoing challenges in the life sciences industry

Re­gen­eron inks $1B+ deal for glob­al rights to Sanofi-part­nered PD-1 Lib­tayo

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Regeneron inks $1B+ deal for global rights to Sanofi-partnered PD-1 Libtayo